Abstract

Failure to publish publicly funded research represents a waste of scarce research resources across medical disciplines and countries. In Switzerland, about 40% of randomised clinical trials (RCTs) supported by the Swiss National Science Foundation (SNSF) were not published. We aimed to describe funding characteristics of published and unpublished RCTs supported by the SNSF, to quantify the amount of money spent for unpublished studies, and to compare our results to a similar study performed in the UK. We established a retrospective cohort of RCTs funded by the SNSF up to 2015. For each RCT proposal, two investigators independently identified corresponding publications in electronic databases and trial registries. Teams of two investigators independently extracted details from the original SNSF proposal and, if available, from trial registries or publications. In addition, we surveyed principal investigators about trial costs and additional sources of funding. We included 101 RCTs supported by the SNSF between 1986 and 2015. Most were single-centre RCTs with a median of 138 participants (interquartile range [IQR] 76-400). Overall, 67 (67%) principal investigators responded to our main survey questions. Median total costs per RCT were CHF 428 000 (IQR 282 000-900 000) of which the SNSF provided a median CHF 222 000 (67% of total costs, IQR 40-80%). Most investigators (70%) mentioned additional funding, mainly from their own institution or private foundations. A total of CHF 6.7 million was granted to RCTs that remained unpublished. Funding characteristics were similar to publicly funded trials in the UK. A third of the total SNSF grant sum spent on healthcare RCTs between 1986 and 2015 did not result in peer-reviewed scientific publications. New SNSF grant schemes might improve publication outcomes but their effectiveness needs to be evaluated.

Highlights

  • Randomised clinical trials (RCTs) are the gold standard for assesing healthcare interventions and a cornerstone of evidence-based medicine [1, 2]

  • We included 101 RCTs supported by the Swiss National Science Foundation (SNSF) between 1986 and 2015

  • A third of the total SNSF grant sum spent on healthcare RCTs between 1986 and 2015 did not result in peer-reviewed scientific publications

Read more

Summary

Introduction

Randomised clinical trials (RCTs) are the gold standard for assesing healthcare interventions and a cornerstone of evidence-based medicine [1, 2]. New regulations and guidelines for RCTs have been published, including initiatives to better protect research participants, improve trial methodology and harmonise research across countries [3,4,5]. These initiatives may have increased research quality, and increased trial complexity and cost. Funding in biomedical research has more than doubled from USD 37.1 billion in 1994 to USD 94.3 billion in 2003, and it has been estimated that clinical trial research costs are increasing by 7.5% per year above the rate of inflation [4, 7, 8].

Objectives
Methods
Results
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call